Volgen
Zenas Yiu
Zenas Yiu
Clinical Senior Lecturer in Dermatology and Pharmacoepidemiology, University of Manchester
Geverifieerd e-mailadres voor manchester.ac.uk - Homepage
Titel
Geciteerd door
Geciteerd door
Jaar
Differential drug survival of biologic therapies for the treatment of psoriasis: a prospective observational cohort study from the British Association of Dermatologists …
RB Warren, CH Smith, ZZN Yiu, DM Ashcroft, JNWN Barker, AD Burden, ...
Journal of Investigative Dermatology 135 (11), 2632-2640, 2015
4272015
British Association of Dermatologists guidelines for biologic therapy for psoriasis 2017
CH Smith, ZK Jabbar‐Lopez, ZZ Yiu, T Bale, AD Burden, LC Coates, ...
British Journal of Dermatology 177 (3), 628-636, 2017
3032017
Factors associated with adverse COVID-19 outcomes in patients with psoriasis—insights from a global registry–based study
SK Mahil, N Dand, KJ Mason, ZZN Yiu, T Tsakok, F Meynell, B Coker, ...
Journal of allergy and clinical immunology 147 (1), 60-71, 2021
1722021
British Association of Dermatologists guidelines for biologic therapy for psoriasis 2020: a rapid update
CH Smith, ZZN Yiu, T Bale, AD Burden, LC Coates, W Edwards, ...
British Journal of Dermatology 183 (4), 628-637, 2020
1652020
Impact of biologic therapies on risk of major adverse cardiovascular events in patients with psoriasis: systematic review and meta‐analysis of randomized controlled trials
W Rungapiromnan, ZZN Yiu, RB Warren, CEM Griffiths, DM Ashcroft
British Journal of Dermatology 176 (4), 890-901, 2017
1462017
Quantitative evaluation of biologic therapy options for psoriasis: a systematic review and network meta-analysis
ZK Jabbar-Lopez, ZZN Yiu, V Ward, LS Exton, MFM Mustapa, ...
Journal of Investigative Dermatology 137 (8), 1646-1654, 2017
1402017
Systemic immunomodulatory treatments for patients with atopic dermatitis: a systematic review and network meta-analysis
AM Drucker, AG Ellis, M Bohdanowicz, S Mashayekhi, ZZN Yiu, ...
JAMA dermatology 156 (6), 659-667, 2020
1322020
Demographics and disease characteristics of patients with psoriasis enrolled in the British Association of Dermatologists Biologic Interventions Register
IYK Iskandar, DM Ashcroft, RB Warren, ZZN Yiu, K McElhone, M Lunt, ...
British Journal of Dermatology 173 (2), 510-518, 2015
1162015
Association Between Tumor Necrosis Factor Inhibitors and the Risk of Hospitalization or Death Among Patients With Immune-Mediated Inflammatory Disease and COVID-19.
JAMA Network Open, 2021
1092021
Drug survival of adalimumab, ustekinumab and secukinumab in patients with psoriasis: a prospective cohort study from the British Association of Dermatologists Biologics and …
ZZN Yiu, KJ Mason, PJ Hampton, NJ Reynolds, CH Smith, M Lunt, ...
British Journal of Dermatology 183 (2), 294-302, 2020
1022020
Systemic immunomodulatory treatments for atopic dermatitis: update of a living systematic review and network meta-analysis
AM Drucker, DE Morra, D Prieto-Merino, AG Ellis, ZZN Yiu, B Rochwerg, ...
JAMA dermatology 158 (5), 523-532, 2022
1002022
Comparison of drug discontinuation, effectiveness, and safety between clinical trial eligible and ineligible patients in BADBIR
KJ Mason, JNWN Barker, CH Smith, PJ Hampton, M Lunt, K McElhone, ...
JAMA dermatology 154 (5), 581-588, 2018
892018
Risk of serious infection in patients with psoriasis receiving biologic therapies: a prospective cohort study from the British Association of Dermatologists Biologic …
ZZN Yiu, CH Smith, DM Ashcroft, M Lunt, S Walton, R Murphy, ...
Journal of Investigative Dermatology 138 (3), 534-541, 2018
842018
Risk of serious infections in patients with psoriasis on biologic therapies: a systematic review and meta-analysis
ZZN Yiu, LS Exton, Z Jabbar-Lopez, MFM Mustapa, EJ Samarasekera, ...
Journal of Investigative Dermatology 136 (8), 1584-1591, 2016
832016
Comparing the efficacy and tolerability of biologic therapies in psoriasis: an updated network meta‐analysis
SK Mahil, MC Ezejimofor, LS Exton, L Manounah, AD Burden, LC Coates, ...
British Journal of Dermatology 183 (4), 638-649, 2020
732020
Drug survival associated with effectiveness and safety of treatment with guselkumab, ixekizumab, secukinumab, ustekinumab, and adalimumab in patients with psoriasis
ZZN Yiu, G Becher, B Kirby, P Laws, NJ Reynolds, CH Smith, RB Warren, ...
JAMA dermatology 158 (10), 1131-1141, 2022
672022
Acne conglobata and adalimumab: use of tumour necrosis factor‐α antagonists in treatment‐resistant acne conglobata, and review of the literature
ZZN Yiu, V Madan, CEM Griffiths
Clinical and Experimental Dermatology 40 (4), 383-386, 2015
612015
Infliximab is associated with an increased risk of serious infection in patients with psoriasis in the UK and Republic of Ireland: results from the British Association of …
ZZN Yiu, DM Ashcroft, I Evans, K McElhone, M Lunt, CH Smith, S Walton, ...
British Journal of Dermatology 180 (2), 329-337, 2019
522019
Safety of biological therapies for psoriasis: effects on reproductive potential and outcomes in male and female patients
ZZN Yiu, CEM Griffiths, RB Warren
British Journal of Dermatology 171 (3), 485-491, 2014
502014
Early‐and late‐onset psoriasis: a cross‐sectional clinical and immunocytochemical investigation
E Theodorakopoulou, ZZN Yiu, C Bundy, L Chularojanamontri, M Gittins, ...
British Journal of Dermatology 175 (5), 1038-1044, 2016
482016
Het systeem kan de bewerking nu niet uitvoeren. Probeer het later opnieuw.
Artikelen 1–20